Because COX-2 is usually specific to inflamed tissue, there is much less gastric irritation associated with COX-2 inhibitors, with a decreased risk of peptic ulceration.
Como o COX-2 é usualmente específica dos tecidos inflamados, hai moita menos irritación gástrica asociada con inhibidores de COX-2, cunha diminución do risco de úlcera péptica.